$PSID CEO and Founder of PositiveID Corporation’
Post# of 102251
(Total Views: 79)
Posted On: 09/19/2017 12:32:44 PM
$PSID CEO and Founder of PositiveID Corporation’s (PSID) ExcitePCR subsidiary.
When asked what makes ExcitePCR’s FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample preparation takes place inside our FireflyDX systems, which means our customers can go from sample capture to answer in 30 minutes or less. On top of that, the FireflyDX devices are small, portable PCR-based units which can be used virtually anywhere around the world. These are just some of the things that set our pathogen detection systems apart from other solutions.”
Later Probst explained, “The reason why this is important is because whenever we experience the beginnings of an outbreak, such as Zika, Ebola, influenza or any other biohazard, rapid identification of who is or isn’t infected is crucial to delivering proper treatment and minimizing the spread of an infectious disease. But one of the biggest barriers to delivering rapid care is (and always has been) preparing samples so they can be tested, quickly and accurately. And this is especially a problem in the field at the Point-of-Care/Point-of-Need. This is the issue we address with our new FireflyDX technologies.”
Probst delivered a brief presentation and answered questions yesterday as a member of a BioWatch panel discussion, officially titled “Novel Technologies to Expand Capabilities,” about current and future advancements in pathogen detection systems, hosted by the National Academies of Science, Engineering, and Medicine (NAS). Internal Sample Preparation, Small Size and Rapid Results Differentiate the FireflyDX Systems, says Lyle Probst During BioWatch Panel
https://finance.yahoo.com/news/internal-sampl...00072.html
When asked what makes ExcitePCR’s FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample preparation takes place inside our FireflyDX systems, which means our customers can go from sample capture to answer in 30 minutes or less. On top of that, the FireflyDX devices are small, portable PCR-based units which can be used virtually anywhere around the world. These are just some of the things that set our pathogen detection systems apart from other solutions.”
Later Probst explained, “The reason why this is important is because whenever we experience the beginnings of an outbreak, such as Zika, Ebola, influenza or any other biohazard, rapid identification of who is or isn’t infected is crucial to delivering proper treatment and minimizing the spread of an infectious disease. But one of the biggest barriers to delivering rapid care is (and always has been) preparing samples so they can be tested, quickly and accurately. And this is especially a problem in the field at the Point-of-Care/Point-of-Need. This is the issue we address with our new FireflyDX technologies.”
Probst delivered a brief presentation and answered questions yesterday as a member of a BioWatch panel discussion, officially titled “Novel Technologies to Expand Capabilities,” about current and future advancements in pathogen detection systems, hosted by the National Academies of Science, Engineering, and Medicine (NAS). Internal Sample Preparation, Small Size and Rapid Results Differentiate the FireflyDX Systems, says Lyle Probst During BioWatch Panel
https://finance.yahoo.com/news/internal-sampl...00072.html
(0)
(0)Scroll down for more posts ▼